Cabozantinib, as a broad-spectrum anti-cancer targeted drug, has shown good clinical efficacy in the treatment of various malignant tumors. Its multi-target inhibitory effect makes it an important choice for cancer treatment.

Clinical efficacy data

(1) Thyroid medullary carcinoma: The median progression free survival was 11.2 months, significantly better than the placebo group.

(2) Renal cell carcinoma: The objective response rate of monotherapy is 17%, and combined immunotherapy can increase it to 48%.

(3) Hepatocellular carcinoma: The median overall survival with second-line treatment is 10.2 months, which is 2.2 months longer than the control group.

Advantages of mechanism of action

(1) Multi target inhibition: Simultaneously targeting 9 kinases such as MET and VEGFR to block tumor growth and metastasis.

(2) Synergistic effect: Combined with immunotherapy, it can improve the tumor microenvironment and enhance treatment efficacy.

Factors affecting therapeutic efficacy

(1) Gene expression: Patients with MET or RET gene abnormalities have a more significant response.

(2) Medication plan: Combination therapy is more effective than monotherapy.

(3) Tolerance: About 60% of patients require dose adjustment, which affects the sustained efficacy.

Special population effects

(1) Pediatric patients: The efficacy of differentiated thyroid cancer patients over 12 years old is comparable to that of adults.

(2) Liver dysfunction: Moderate damage patients need to reduce dosage, otherwise it will affect the efficacy and safety.